
Big Food Invests Millions in Rebrands as GLP-1 Drugs Reshape Demand
Global food giants like PepsiCo and Coca-Cola are ramping up investments in rebranded, protein-rich products as GLP-1 drugs suppress appetite and alter eating habits across 20% of U.S. households. With potential $12 billion in lost snack sales over the next decade, companies are shifting to smaller portions and nutrient-dense options. This adaptation highlights the lasting ripple effects of obesity medications on the food industry.







